This segment focuses on the research, development, manufacturing, and commercialization of insulin analogs for the treatment of diabetes. Gan & Lee's portfolio includes insulin glargine, insulin lispro, and insulin aspart injections. R&D efforts are directed towards improving the efficacy, safety, and convenience of insulin therapies. The company employs advanced protein engineering and formulation technologies to develop novel insulin analogs with improved pharmacokinetic and pharmacodynamic profiles. Clinical trials are conducted to evaluate the safety and efficacy of these products in diverse patient populations. This segment addresses the critical need for effective glycemic control in patients with diabetes, aiming to reduce the risk of long-term complications and improve quality of life. Gan & Lee's market positioning is strengthened by its focus on innovation and its commitment to providing affordable insulin therapies to patients in China and globally. Future opportunities include expanding the product pipeline with novel insulin formulations and delivery systems.

This segment is dedicated to the discovery and development of innovative drugs beyond insulin, targeting various therapeutic areas including oncology and metabolic diseases. Gan & Lee leverages its expertise in drug discovery and development to identify and advance promising drug candidates through preclinical and clinical studies. The company employs a range of technologies, including antibody-drug conjugates and small molecule inhibitors, to develop targeted therapies with improved efficacy and safety profiles. Clinical trials are conducted to evaluate the safety and efficacy of these novel drug candidates in specific patient populations. This segment aims to address unmet medical needs in areas such as cancer and metabolic disorders, with a focus on developing innovative therapies that can improve patient outcomes. Gan & Lee's market positioning is enhanced by its commitment to innovation and its ability to translate scientific discoveries into clinical applications. Future opportunities include expanding the pipeline with novel drug candidates and exploring strategic partnerships to accelerate drug development.